<DOC>
	<DOC>NCT00784186</DOC>
	<brief_summary>The primary goal of this study is to determine the clinical advantage of pre-treatment with mifepristone in second trimester misoprostol induction abortion. This will be a randomized controlled double-blinded trial of 260 women comparing misoprostol alone to mifepristone plus misoprostol for second trimester (14-21 weeks' LMP) medical abortion.</brief_summary>
	<brief_title>Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial</brief_title>
	<detailed_description />
	<mesh_term>Mifepristone</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>14 to 21 weeks gestation, based on menstrual history and clinical exam (with or without ultrasound) Meet legal criteria to obtain abortion Present with closed cervical os and no vaginal bleeding Live fetus at time of presentation for service Have no contraindications to study procedures, according to provider Be able to consent to procedure, either by reading consent document or by having consent document read to her Be willing to follow study procedures Known previous transmural uterine incision Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol Any contraindications to vaginal delivery, including placenta previa Presentation in active labor (defined as moderate to severe contractions every 10 minutes or less)</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Pregnancy termination</keyword>
	<keyword>abortion</keyword>
	<keyword>medical abortion</keyword>
	<keyword>2nd trimester</keyword>
	<keyword>mifepristone</keyword>
	<keyword>misoprostol</keyword>
</DOC>